Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients

European Journal of Neurology

Volumn 19, Issue 10, 2012, Pages 1337-1342

  Carpentier, A F ^a,b,c   Ferrari, D ^a   Bailon, O ^a,b   Ursu, R ^a   Banissi, C ^a   Dubessy, A L ^a   Belin, C ^a   Levy, C ^d  

^a AVICENNE HOSPITAL   (France)

^b National Institute for Health Surveillance   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Institut de Radiothérapie de Bobigny   (France)

Author keywords

Angiotensin II; Edema; Glioblastoma; Radiotherapy; Steroids

Indexed keywords

ANGIOTENSIN II ANTAGONIST; METHYLPREDNISOLONE; PREDNISOLONE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN EDEMA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRAIN EDEMA; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84866294847     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03766.x     Document Type: Article

References (25)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumors in adults. Lancet 2003; 361: 323-331.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Marantidou A, Levy C, Duquesne A, et al. Steroid requirements during radiotherapy for malignant gliomas. J Neurooncol 2010; 100: 89-94.
4. Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008; 16: 1041-1048.
5. Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 2002; 10: 322-328.
6. Heiss JD, Papavassiliou E, Merrill MJ. Mechanism of dexamethasone suppression of brain-tumor associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996; 98: 1400-1408.
7. Patel N, Sun L, Moshinsky D, et al. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J Pharmacol Exp Ther 2003; 306: 838-845.
8. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995; 25: 913-917.
9. Marrero MB, Schieffer B, Bernstein KE, Ling BN. Angiotensin II-induced tyrosine phosphorylation in mesangial and vascular smooth muscle cells. Clin Exp Pharmacol Physiol 1996; 23: 83-88.
10. Andrade SP, Cardoso CC, Machado RD, Beraldo WT. Angiotensin-II-induced angiogenesis in sponge implants in mice. Int J Microcirc Clin Exp 1996; 16: 302-307.
11. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998; 1401: 187-194.
12. Imai N, Hashimoto T, Kihara M, et al. Roles for host and tumor angiotensin II type 1 receptor in tumor growth and tumor-associated angiogenesis. Lab Invest 2007; 87: 189-198.
13. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294: 441-447.
14. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112: 67-75.
15. Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11: 2686-2694.
16. Rivera E, Arrieta O, Guevara P, Duarte-Rojo A, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 2001; 85: 1396-1399.
17. Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomised clinical trial. J Clin Oncol 2004; 22: 1583-1588.
18. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 2002; 200: 639-646.
19. Sano H, Hosokawa K, Kidoya H, Takakura N. Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler Thromb Vasc Biol 2006; 26: 2673-2680.
20. Sur P, Sribnick EA, Patel SJ, et al. Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. Glia 2005; 50: 160-167.
21. Lever A, Hole D, Gillis C, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-184.
22. Friis S, Sørensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462-2470.
23. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 2008; 112: 748-757.
24. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
25. Kirste S, Treier M, Wehrle SJ, et al. Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer 2011; 117: 3788-3795.